Herzele, Belgium

Lieven Jozef Stuyver

This inventor holds 30 USPTO granted patents and 10 published patent applications, plus 1 CIPO patent and 10 EPO patents, primarily in HIV and HCV Diagnostics. Top assignees: Innogenetics N.v., N.v. Innogenetics S.a., Innogenetics, S.a.. Active years: 1998-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lieven Jozef Stuyver. Retrieved from https://idiyas.com/inventor/lieven-jozef-stuyver

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 30 

% Patents Active = 30.0

 

 

Average Co-Inventor Count = 2.8

ph-index = 7

Forward Citations = 126(Granted Patents)


Location History:

  • Borsbeke, BE (1998 - 2007)
  • Lede, BE (2004 - 2010)
  • Herzele, BE (2003 - 2017)
  • Beerse, BE (2019)

Company Filing History:


Years Active: 1998-2019

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
HIV Assay
HCV Typing
Drug Resistance
Viral Load Detection
Therapeutic Agents
Diagnostic Agents
Hepatitis C
Hepatitis B
Mutation Detection
Phenotype Assay
30 patents (USPTO):Explore Patents

Title: Innovations by Lieven Jozef Stuyver in Drug Resistance and HIV Treatment

Introduction

Lieven Jozef Stuyver, an accomplished inventor based in Herzele, Belgium, has made significant contributions to the fields of virology and pharmacology. With an impressive portfolio of 29 patents, he has developed innovative methods that enhance the understanding and treatment of viral infections, particularly HIV and Hepatitis C Virus (HCV).

Latest Patents

Two of his notable recent patents include:

1. **Method for Designing a Drug Regime for HIV-Infected Patients**

This patent details a novel genotype and phenotype assay that helps to elucidate and evaluate new potential HIV integrase inhibitors, as well as approved and experimental compounds that target protease, reverse transcriptase, and RNaseH. This innovative assay allows for the study of linked mutations and mutational patterns that occur under Highly Active Antiretroviral Therapy (HAART) and experimental therapies.

2. **Method for Determining Drug Resistance Mutations in Any of the Non-Structural Protein Regions NS3 to NS5B of Hepatitis C Virus for Genotypes 1 to 6**

This invention relates to a method that determines drug resistance mutations within the non-structural protein regions NS3 to NS5B of HCV for genotypes 1 to 6, specifically targeting subtype-specific genotypes such as 1a, 1b, 2a, 2b, 3a, 4a, and 4d.

Career Highlights

Throughout his career, Lieven Jozef Stuyver has worked at prominent companies, including Innogenetics N.V. and Innogenetics S.A. His work at these institutions has fostered advancements in molecular virology and antiviral drug development.

Collaborations

Lieven has collaborated with esteemed colleagues in his field, such as Geert Maertens and Rudi Rossau, leveraging their expertise to further enhance innovation and research outcomes in antiviral therapies.

Conclusion

With a robust portfolio of patents and a commitment to advancing treatment methodologies, Lieven Jozef Stuyver has established himself as a key figure in the fight against viral infections. His contributions not only pave the way for future innovations but also significantly improve patient outcomes in managing HIV and Hepatitis C.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…